Rigel Pharmaceuticals (RIGL) Assets Average (2011 - 2026)

Rigel Pharmaceuticals' Assets Average history runs 16 years deep, the most recent figure standing at $509.1 million for Q1 2026.

• On a quarterly basis, Assets Average rose 199.52% year-over-year to $509.1 million in Q1 2026; TTM through Mar 2026 was $509.1 million, a 199.52% increase from a year earlier, with the FY2025 full-year figure at $338.8 million, up 140.96% from the prior year.
• Assets Average climbed to $509.1 million in Q1 2026 per RIGL's latest filing, from $378.1 million in the prior quarter.
• Across five years, Assets Average topped out at $509.1 million in Q1 2026 and bottomed at $116.2 million in Q3 2023.
• The 5-year median for Assets Average is $133.9 million (2024), against an average of $178.4 million.
• Across the five-year window, Assets Average slumped 37.23% in 2022 and surged 199.52% in 2026, its largest moves.
• Year by year, Assets Average stood at $124.9 million in 2022, then decreased by 6.94% to $116.3 million in 2023, then surged by 30.46% to $151.7 million in 2024, then soared by 149.22% to $378.1 million in 2025, then surged by 34.66% to $509.1 million in 2026.
• Per Business Quant, the three latest RIGL Assets Average figures stand at $509.1 million (Q1 2026), $378.1 million (Q4 2025), and $224.6 million (Q3 2025).